title: Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis.
abstract: Fifty-seven patients receiving unrelated donor (UD) BMT were matched for disease and stage with 57 recipients of genotypically matched related donor (MRD) BMT. All UD recipients were matched serologically for A and B and by high resolution for DR and DQ antigens. All patients received CsA and 'short course' methotrexate with folinic acid. Unrelated donor BMT patients also received thymoglobulin 4.5 mg/kg (6 mg/kg if <30 kg) in divided doses over 3 days pretransplant. For UD and RD BMT, respectively, incidence of acute GVHD grade II-IV was 19 +/- 6% vs 36 +/- 8%, grade III-IV 10 +/- 6% vs 18 +/- 7%, chronic GVHD 44 +/- 8% vs 51 +/- 8%, non-relapse mortality 15 +/- 5% vs 8 +/- 4% at 100 days, 28 +/- 8% vs 36 +/- 7% at 3 years. At 3 years, relapse was 45 +/- 7% vs 42 +/- 7%, and disease-free survival 39 +/- 7% vs 37 +/- 7%. None of these differences are significant. Three-year overall survival was identical at 42 +/- 7%. For 29 patients with low/intermediate risk leukemia, disease-free survival was 68 +/- 10% after UD BMT vs 59 +/- 9% for RD BMT recipients (P = NS). Corresponding figures for high risk patients were 14 +/- 7% and 21 +/- 8%, respectively. We conclude that UD BMT recipients matched as above and given pretransplant ATG have similar outcomes to recipients of MRD BMT using conventional drug prophylaxis. Unrelated donor BMT should be considered in any circumstance where MRD BMT is routine.
authors.affiliation: Department of Medicine, Foothills Hospital, Calgary, Alberta, Canada.
authors.forename: P
authors.initials: P
authors.lastname: Duggan
authors.forename: K
authors.initials: K
authors.lastname: Booth
authors.forename: A
authors.initials: A
authors.lastname: Chaudhry
authors.forename: D
authors.initials: D
authors.lastname: Stewart
authors.forename: J D
authors.initials: JD
authors.lastname: Ruether
authors.forename: S
authors.initials: S
authors.lastname: Glück
authors.forename: D
authors.initials: D
authors.lastname: Morris
authors.forename: C B
authors.initials: CB
authors.lastname: Brown
authors.forename: B
authors.initials: B
authors.lastname: Herbut
authors.forename: M
authors.initials: M
authors.lastname: Coppes
authors.forename: R
authors.initials: R
authors.lastname: Anderson
authors.forename: J
authors.initials: J
authors.lastname: Wolff
authors.forename: M
authors.initials: M
authors.lastname: Egeler
authors.forename: S
authors.initials: S
authors.lastname: Desai
authors.forename: A R
authors.initials: AR
authors.lastname: Turner
authors.forename: L
authors.initials: L
authors.lastname: Larratt
authors.forename: E
authors.initials: E
authors.lastname: Gyonyor
authors.forename: J A
authors.initials: JA
authors.lastname: Russell
mesh_terms: D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation / Q000276:immunology / Q000379:methods* / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D005838:Genotype; D006086:Graft vs Host Disease / Q000517:prevention & control; D006650:Histocompatibility Testing / Q000379:methods; D006801:Humans; D008297:Male; D016555:Matched-Pair Analysis; D011379:Prognosis; D012008:Recurrence; D015996:Survival Rate; D014019:Tissue Donors; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum